Genetesis IPO

genetesis.com

Genetesis is a biopharma company focusing on the treatment of heart diseases and chest pain using digital and electric imaging technology. Genetesis has developed its Cardioflux imaging device, in which a patient can pass through, and by using magnetocardiography, it can pick up natural magnetic signals produced in the heart for optimal treatment and diagnosis options. Genetesis partners with healthcare organizations to bring its devices to the patients that could benefit from this type of cardiac care.

Founded2013
Register for Details

For more details on financing and valuation for Genetesis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Genetesis Ticker Symbol

Genetesis does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Genetesis Stock Price

The stock price for Genetesis will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Genetesis

Mithril Capital Management
Ohio Innovation Fund
JobsOhio Growth Capital Fund
CincyTech
Cercano Management

Other companies like Genetesis in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM